Announcements Trials
Browse Landscape

Phase

Phase 3 28Phase 2 26Phase 1 6Phase 2/3 4Phase NA 3Phase 1/2 3

Status

Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Nasopharyngeal Carcinoma 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Virus Diseases 1Urethral Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Liver Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 6Gemcitabine 4Fluorouracil 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2Platinum 21,2-diaminocyclohexaneplatinum II citrate 2dehydroftorafur 1camrelizumab 1atezolizumab 1Watchful Waiting 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Drug Therapy 1Docetaxel 1Disulfides 1Cetuximab 1Carboplatin 1Bevacizumab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Nasopharyngeal Carcinoma × Gemcitabine × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
460 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04890522 2021-05-18

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Sun Yat-sen University

Phase 2/3 Not yet recruiting
622 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT01854203 2013-07-30

NPC

Sun Yat-sen University

Phase 2/3 Unknown
300 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡